Heidelberg Pharma, a subsidiary of Wilex AG, and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) have signed a license agreement on a set of anti-BCMA antibodies generated at the MDC. The deal follows an option agreement between the partners mediated by Ascenion last September.
Based on the MDC antibodies Heidelberg Pharma has developed an antibody-toxin conjugate which has strong potential to combat multiple myeloma, the third most common haematological cancer.
The candidate is expected to start clinical trials by the end of 2018.
For further information:
MCD newsletter from January 2017
Ascenion’s press release on the option agreement from September 2016